SCHEMBL70968

SCHEMBL70968

CCOC(=O)C(=O)CC(=O)c1ccccc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ERCC5 P28715 3/20 0.58
FEN1 P39748 3/20 0.58
PTPN1 P18031 1/20 0.58
KMT2A Q03164 6/20 0.56
MEN1 O00255 5/20 0.56
ALDH1A1 P00352 3/20 0.56
MAPT P10636 2/20 0.56
NPC1 O15118 2/20 0.56
SMN1; SMN2 Q16637 3/20 0.55
KDM4E B2RXH2 1/20 0.55
CYP3A4 P08684 1/20 0.55
HPGD P15428 1/20 0.55
ALOX15 P16050 1/20 0.55
CES1 P23141 1/20 0.55
MAPK1 P28482 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
POLB P06746 2/20 0.55
RAB9A P51151 1/20 0.55
GLA P06280 1/20 0.49
CYP19A1 P11511 2/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11087897 0.92 KMT2A (0.51) ERCC5FEN1PTPN1KMT2AMEN1
SCHEMBL6365441 0.90 HAO1 (0.63) ERCC5FEN1PTPN1KMT2AMEN1
SCHEMBL19545100 0.88 ERCC5 (0.68) ERCC5FEN1KMT2AMEN1ALDH1A1
SCHEMBL2911004 0.86 ALDH1A1 (0.58) KMT2AMEN1ALDH1A1MAPTNPC1
SCHEMBL9208969 0.84 ALDH1A1 (0.57) ERCC5FEN1KMT2AMEN1ALDH1A1
SCHEMBL12020298 0.84 ESR1 (0.58) PTPN1KMT2AALDH1A1MAPTNPC1
SCHEMBL12182346 0.84 SMN1; SMN2 (0.51) ERCC5FEN1PTPN1KMT2AMEN1
SCHEMBL2910361 0.83 SMN1; SMN2 (0.57) ERCC5FEN1KMT2AMEN1ALDH1A1
SCHEMBL1109662 0.83 ERCC5 (0.64) ERCC5FEN1PTPN1KMT2AMEN1
SCHEMBL25011313 0.83 ALDH1A1 (0.56) ERCC5FEN1KMT2AMEN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2026087561-A1 RETARDING AGENT IN ISOCYANATE COMPONENT OF POLYURETHANE/UREA CEMENTITIOUS HYBRID SYSTEMS SIKA TECHNOLOGY AG (CH) 2026-04-30 WO claimed
EP-4733284-A1 RETARDING AGENT IN ISOCYANATE COMPONENT OF POLYURETHANE/UREA CEMENTITIOUS HYBRID SYSTEMS Sika Technology AG (CH) 2026-04-29 EP claimed
EP-4063422-A1 1,3-DICARBONYL COMPOUNDS AS RETARDING ADDITIVES FOR UCRETE SYSTEMS Construction Research & Technology GmbH (DE) 2022-09-28 EP claimed
CN-103898072-B A kind of Ketoreductase mutant and application thereof HANGZHOU NORMAL UNIVERSITY (CN) 2016-03-16 CN claimed
CN-103898072-A Ketoreductase mutant and application thereof UNIV HANGZHOU NORMAL 2014-07-02 CN claimed
WO-2026087561-A1 RETARDING AGENT IN ISOCYANATE COMPONENT OF POLYURETHANE/UREA CEMENTITIOUS HYBRID SYSTEMS SIKA TECHNOLOGY AG (CH) 2026-04-30 WO disclosed
EP-4733284-A1 RETARDING AGENT IN ISOCYANATE COMPONENT OF POLYURETHANE/UREA CEMENTITIOUS HYBRID SYSTEMS Sika Technology AG (CH) 2026-04-29 EP disclosed
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY HOTSPOT THERAPEUTICS INC (US) 2026-03-26 US disclosed
US-20250353851-A1 PURINES AND METHODS OF THEIR USE KINETA INC (US) 2025-11-20 US disclosed
CN-119031913-A Purine and methods of use thereof 奇尼塔公司 2024-11-26 CN disclosed
EP-4444312-A2 PURINES AND METHODS OF THEIR USE Kineta, Inc. (US) 2024-10-16 EP disclosed
US-20240208923-A1 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION JNANA THERAPEUTICS INC. 2024-06-27 US disclosed
US-4211709-A ANTIINFLAMMATORY AGENTS, CENTRAL NERVOUS SYSTEM DEPRESSANTS GRUPPO LEPETIT S.P.A. (IT) 1980-07-08 US disclosed
US-4198502-A ANTIINFLAMMATORY AGENT, CNS DEPRESSANTS, ANALGESICS, ANTIPYRETICS, ANTIULCER AGENTS GRUPPO LEPETIT S.P.A. (IT) 1980-04-15 US disclosed
US-4190726-A Polycyclic dyestuffs BAYER AKTIENGESELLSCHAFT (DE) 1980-02-26 US disclosed
US-4140696-A ANTIINFLAMMATORY AGENTS, ANALGESICS, ANTIPYRETICS AND CNS DEPRESSANTS GRUPPO LEPETIT S.P.A. (IT) 1979-02-20 US disclosed
EP-0000541-A2 1H-Pyrimido-(4,5-c)-1,2-diazepines, methods for their preparation and compositions containing them; their use as intermediates for heterocyclic transformations. THE WELLCOME FOUNDATION LIMITED (GB) 1979-02-07 EP disclosed
EP-0000383-A1 Pyrimido (4,5-c) pyridazines, their use in pharmaceutical preparations, and process for their preparation THE WELLCOME FOUNDATION LIMITED (GB) 1979-01-24 EP disclosed
EP-0000382-A1 Pyrimido (4,5-c)pyridazines, compositions containing them and processes for their preparation THE WELLCOME FOUNDATION LIMITED (GB) 1979-01-24 EP disclosed
US-4007180-A POLYESTERS HOECHST AKTIENGESELLSCHAFT (DT) 1977-02-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240208923-A1 SMALL MOLECULE INHIBITORS OF MAMMALIAN SLC6A19 FUNCTION SLC18A2, SLC6A19, SLC1A1 ERCC5 3785/4885FEN1 3013/4885PTPN1 3751/4885
US-20260085073-A1 PYRAZOLYLCARBOXAMIDE COMPOUNDS AND THEIR USE IN THERAPY MALT1, BCL6, BCL3 ERCC5 4283/4885FEN1 1981/4885PTPN1 353/4885
US-20250353851-A1 PURINES AND METHODS OF THEIR USE TDP1, TDP2, PIKFYVE ERCC5 654/4885FEN1 82/4885PTPN1 4084/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.